Latest Strategy News

HUB24 Limited has announced a fully franked ordinary dividend of AUD 0.36 per share for the six months ending December 2025, signalling steady returns for shareholders.

Transurban Group posted robust half-year results for December 2025, with revenue climbing 8.1% and profit rebounding to $343 million. The company also declared a 34-cent interim distribution, underpinned by strong cash flow and key project milestones.

Medibank Private Limited reported a 6% rise in operating profit for the half-year ended December 2025, despite an 11% drop in net profit after tax amid ongoing cybercrime-related costs and legal challenges. The company also raised its interim dividend by 6.4%, signalling confidence in its capital position and growth strategy.

Telstra Group Limited reported solid half-year results for December 2025, with revenue and profit growth underpinning a higher dividend and an expanded share buy-back program. The company’s Connected Future 30 strategy continues to drive operational momentum amid disciplined cost management.

Spheria Emerging Companies Limited has reported a solid 16.8% increase in profit after tax for the half-year ending December 2025, alongside a strategic shift introducing monthly fully franked dividends.

MEC Resources Ltd reported a half-year loss of $431,971 amid ongoing legal challenges over key gas exploration permits, while progressing investments in clean energy and neurotechnology. The company also completed a $359K options placement, reinforcing its financial position.

Global X Management (AUS) Limited has announced estimated distributions for three ETFs listed on the ASX AQUA Market for the period ending 28 February 2026, providing key dates and dividend reinvestment plan eligibility.

Austco Healthcare has reported a robust first half of 2026, with revenue surging 31% and EBITDA jumping 60%, underpinned by solid contract backlog and debt-free balance sheet.

IGNITE Limited reports a challenging first half of FY26 with an 18% revenue decline and a halving of statutory profit, yet maintains a fully franked interim dividend amid a strategic business closure.

Alcoa of Australia has partnered with the federal government to overhaul the environmental approvals process for its Western Australian mining operations, committing $55 million to conservation efforts and securing operational certainty through 2045.

AuMEGA Metals has successfully upsized its institutional financing to C$30.1 million, anchored by Condire Investors who will hold nearly 20% of the company. The funds will accelerate exploration programs across its Newfoundland gold projects.

Nyrada Inc. reported a $3.19 million loss for the half-year ending December 2025, while advancing its lead drug candidate Xolatryp® into Phase IIa clinical trials targeting heart attack treatment.